111 related articles for article (PubMed ID: 19562617)
1. A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
Reddy KS; Schwartz GE; Jamedhor M
Leuk Lymphoma; 2009 Aug; 50(8):1375-80. PubMed ID: 19562617
[No Abstract] [Full Text] [Related]
2. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Bee PC; Gan GG; Nadarajan VS; Latiff NA; Menaka N
Int J Hematol; 2010 Jan; 91(1):136-9. PubMed ID: 20047097
[TBL] [Abstract][Full Text] [Related]
3. Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Ostro D; Cheung K; Kamel-Reid S; Lipton JH
Leuk Lymphoma; 2007 May; 48(5):1029-31. PubMed ID: 17487749
[No Abstract] [Full Text] [Related]
4. Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Godley LA
Leuk Lymphoma; 2009 Jun; 50(6):871-2. PubMed ID: 19479615
[No Abstract] [Full Text] [Related]
5. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
[No Abstract] [Full Text] [Related]
6. Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Perel JM; McCarthy C; Walker O; Irving I; Williams B; Kennedy GA
Haematologica; 2005 Nov; 90 Suppl():ECR25. PubMed ID: 16266916
[No Abstract] [Full Text] [Related]
7. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Cesar JM; Cabello P; Ferro T; Navarro JL
Cancer Genet Cytogenet; 2006 May; 167(1):74-7. PubMed ID: 16682291
[TBL] [Abstract][Full Text] [Related]
8. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Cambier N; Renneville A; Cazaentre T; Soenen V; Cossement C; Giraudier S; Grardel N; Laï JL; Rose C; Preudhomme C
Leukemia; 2008 Jul; 22(7):1454-5. PubMed ID: 18288134
[No Abstract] [Full Text] [Related]
9. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
[TBL] [Abstract][Full Text] [Related]
10. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Pieńkowska-Grela B; Rygier J; Woroniecka R; Grygalewicz B; Pastwińska A; Krawczyk P; Ceglerek B; Seferyńska I; Sikorska A; Konopka L
Leuk Lymphoma; 2009 Jun; 50(6):952-65. PubMed ID: 19479611
[TBL] [Abstract][Full Text] [Related]
11. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Pavlu J; Czepulkowski B; Kaczmarski R; Jan-Mohamed R
Lancet Oncol; 2005 Feb; 6(2):128. PubMed ID: 15683824
[No Abstract] [Full Text] [Related]
12. A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia.
Vaidya S; Joshi D; Ghosh K; Chakrabarti P; Vundinti BR
Hum Pathol; 2013 Oct; 44(10):2365-9. PubMed ID: 23759653
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
14. [Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
Jomen W; Kuroda H; Matsuno T; Sato M; Yamada M; Abe T; Sakurai T; Fujii S; Maeda M; Fujita M; Kato J; Nojiri S
Rinsho Ketsueki; 2014 Mar; 55(3):360-5. PubMed ID: 24681942
[TBL] [Abstract][Full Text] [Related]
15. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
16. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
Andersen MK; Pedersen-Bjergaard J; Kjeldsen L; Dufva IH; Brøndum-Nielsen K
Leukemia; 2002 Jul; 16(7):1390-3. PubMed ID: 12094265
[No Abstract] [Full Text] [Related]
17. Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
Tunca Y; Güran S
Exp Hematol; 2005 Feb; 33(2):151. PubMed ID: 15676207
[No Abstract] [Full Text] [Related]
18. Chronic myelogenous leukemia.
O'Brien S; Berman E; Bhalla K; Copelan EA; Devetten MP; Emanuel PD; Erba HP; Greenberg PL; Moore JO; Przepiorka D; Radich JP; Schilder RJ; Shami P; Smith BD; Snyder DS; Soiffer RJ; Tallman MS; Talpaz M; Wetzler M
J Natl Compr Canc Netw; 2005 Nov; 3(6):732-55. PubMed ID: 16316611
[No Abstract] [Full Text] [Related]
19. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
20. Trisomy X in Philadelphia chromosome-negative cells during the course of Philadelphia chromosome-positive chronic myelocytic leukemia.
Hishida A; Yamamoto K; Matsushita T; Tanimoto M; Saito H; Emi N
Cancer Genet Cytogenet; 2003 Apr; 142(1):83-5. PubMed ID: 12660041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
